Alleviant Medical, Inc.
Alleviant Medical is dedicated to developing innovative, safe, and effective treatments for heart failure, focusing on a no-implant interatrial shunt system. Their mission is to lift the burden of heart failure by providing new therapeutic options, including the investigational Alleviant System, which aims to reduce symptoms and improve quality of life for patients with heart failure, especially those with HFpEF.
Industries
Nr. of Employees
small (1-50)
Alleviant Medical, Inc.
7801 N Lamar Blvd, Suite D-106, Austin, TX 78752 USA
Patents
Products
Investigational no-implant interatrial shunt system
A transcatheter system intended to create a durable interatrial communication via catheter-based tissue excision without leaving a permanent implant, designed to reduce left atrial pressure in selected heart failure patients.
Investigational no-implant interatrial shunt system
A transcatheter system intended to create a durable interatrial communication via catheter-based tissue excision without leaving a permanent implant, designed to reduce left atrial pressure in selected heart failure patients.
Services
Sponsorship, coordination and execution of multicenter clinical trials to evaluate safety and efficacy of investigational interatrial shunt therapy, including site selection, patient enrollment and outcome data collection.
Sponsorship, coordination and execution of multicenter clinical trials to evaluate safety and efficacy of investigational interatrial shunt therapy, including site selection, patient enrollment and outcome data collection.
Expertise Areas
- Interventional cardiology procedures
- Clinical trial management and design (randomized, sham-controlled, adaptive)
- Heart failure therapeutics and hemodynamic phenotyping
- Device development for transcatheter interventions
Key Technologies
- Transcatheter catheter-based device delivery
- Transseptal puncture technique
- Electrosurgical tissue excision (septectomy)
- Intraprocedural echocardiography
News & Updates
Alleviant Medical's Alleviant System received a Breakthrough Device Designation from the U.S. FDA, highlighting its potential in treating heart failure.
The company secured $75 million in financing and received FDA IDE approval to proceed with a pivotal clinical trial for their heart failure treatment system.
Alleviant Medical announced securing $90 million to expand their clinical trial program for interventional heart failure treatment.
Recent clinical data on the Alleviant System shows promising results in treating heart failure without leaving a permanent implant.
A study discussing the feasibility of a no-implant approach to interatrial shunting for heart failure treatment.
Six-month clinical outcomes from multicenter studies on no-implant interatrial shunt for HFpEF patients.
Alleviant Medical's Alleviant System received a Breakthrough Device Designation from the U.S. FDA, highlighting its potential in treating heart failure.
The company secured $75 million in financing and received FDA IDE approval to proceed with a pivotal clinical trial for their heart failure treatment system.
Alleviant Medical announced securing $90 million to expand their clinical trial program for interventional heart failure treatment.
Recent clinical data on the Alleviant System shows promising results in treating heart failure without leaving a permanent implant.
A study discussing the feasibility of a no-implant approach to interatrial shunting for heart failure treatment.
Six-month clinical outcomes from multicenter studies on no-implant interatrial shunt for HFpEF patients.